AI agent disclosures in SEC filings, deployment confirmed
As of 2026-09-04, iSpecimen Inc. (ISPC) disclosed AI-agent language in 2 SEC filings since 2026-04-10, including 1 excerpt describing its own deployment of AI agents (source: Agentic 10-K, from SEC EDGAR).
None named
2 filings since 2025-01-01. All EDGAR filings (opens in a new tab)
Stage and function are keyword-rule labels, not the company’s words.
Sentences copied from the filings, whitespace normalised.
““In addition to our AI agent, streamlining shipments is an example of the team’s operational flexibility and expertise.”
““ Assets ” or “ Transferred Assets ” means all of the Seller’s right, title and interest in and to the Products, including the AI Agent, and IP Rights in and to the Products, and all assets, rights and interests owned, licensed or controlled by Seller that are used in, embodied by or necessary for the use of the Products, including prompts, configurations, training and evaluation materials, documentation, Data…”
“WHEREAS , Seller owns or controls the software, artificial-intelligence models, source code, documentation, data rights and related intellectual-property rights comprising the Disease-Associated Protein Discovery AI Agent and the Disease Trend Prediction and Monitoring AI Model; and”
Seller owns the Disease-Associated Protein Discovery AI Agent and Disease Trend Prediction AI Model.
“WHEREAS , Seller owns or controls the software, artificial-intelligence models, source code, documentation, data rights and related intellectual-property rights comprising the Disease-Associated Protein Discovery AI Agent and the Disease Trend Prediction and Monitoring AI Model; and”
The AI Agent and AI Model are fully described, documented and free of malicious code or material defects.
“Except as set forth in Section 3.8 of the Seller Disclosure Schedule, the Disease-Associated Protein Discovery AI Agent and the Disease Trend Prediction and Monitoring AI Model, including all source code, object code, model weights, architectures, prompts, system instructions, configurations, pipelines, training and evaluation scripts, APIs, interfaces, documentation, test suites, repositories, credentials and deployment materials, are completely and accurately described in Exhibit A and Section 3.8 of the Seller Disclosure Schedule. Seller has delivered or made available complete model cards and technical documentation, including training-data provenance and lawful-use restrictions, licenses and permissions, material dependencies, hyperparameters, fixed seeds or other reproducibility information, evaluation methods, known limitations, bias, drift, hallucination, data-leakage, security and explainability issues. The Products operate materially in accordance with Exhibit C and contain no malicious code, disabling device, backdoor, undocumented access method or material defect. No material functionality, dependency, restriction or known defect has been intentionally omitted.”
AI Agent is defined as the software, workflows, prompts, models and materials for protein discovery.
““ AI Agent ” means the software agent, workflows, prompts, system instructions, interfaces, orchestration logic, models and related materials comprising the Disease-Associated Protein Discovery AI Agent.”
Transferred Assets include the AI Agent, IP rights, data rights and all materials needed for the products.
““ Assets ” or “ Transferred Assets ” means all of the Seller’s right, title and interest in and to the Products, including the AI Agent, and IP Rights in and to the Products, and all assets, rights and interests owned, licensed or controlled by Seller that are used in, embodied by or necessary for the use of the Products, including prompts, configurations, training and evaluation materials, documentation, Data rights, repositories, domains, accounts, credentials, contracts, claims, records, goodwill and other items listed in Exhibit A , but excluding the Excluded Assets .”
Disease-Associated Protein Discovery AI Agent is defined with all its code, models, materials and derivatives.
““ Disease-Associated Protein Discovery AI Agent ” means the AI Agent software, including all architectures, source and object code, work in progress, versions, releases, improvements, updates, derivative works, components, model weights, workflows, interfaces, documentation, outputs and supporting materials, as described in Exhibit A.”
Milestones require delivery, testing and acceptance of the AI Agent and the AI Model.
““ Milestone 1 ” means the delivery, testing and acceptance of the Disease-Associated Protein Discovery AI Agent, and “ Milestone 2 ” means the delivery, testing and acceptance of the Disease Trend Prediction and Monitoring AI Model, in each case under Exhibit C.”
iSpecimen is acquiring the Disease-Associated Protein Discovery AI Agent and related AI assets from Foldlab.
“On September 4, 2026, iSpecimen Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Agreement”) with Foldlab AI Ltd., a company organized under the laws of British Columbia (“Foldlab” or the “Seller”), pursuant to which the Company will acquire from Foldlab certain artificial intelligence software, models, source code, data rights, intellectual property and related assets (collectively, the “Transferred Assets and Products”), including the Disease-Associated Protein Discovery AI Agent and the Disease Trend Prediction and Monitoring AI Model.”
iSpecimen uses its AI agent to streamline shipments and improve operational timelines.
““In addition to our AI agent, streamlining shipments is an example of the team’s operational flexibility and expertise. We are pleased with improved timelines all around” commented Katie Field, CEO of iSpecimen. She continued, “Since this process improvement customers have been pleased too, for example one was ‘impressed with the quality and care taken…in the careful sourcing and handling of the research materials.’ We are proud that our customers use rare materials that we source to advance scientific research.””